Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
A US district court has denied Zydus Cadila’s motion for summary judgment on Sherman Act antitrust counterclaims against Takeda over a branded formulation of lansoprazole, finding that the originator did have basis to sue the ANDA sponsor again in 2018.
Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.
The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.
The long-running process of setting up a new European patent court and unitary patent system should shortly be moving into its final phase following a ruling by a German constitutional court.
After the WHO recommended the use of IL-6 receptor blockers to treat patients hospitalized with severe or critical COVID-19, Actemra/RoActemra originator Roche pledged not to enforce IP covering the tocilizumab brand in low- and middle-income countries during the pandemic. But humanitarian organization MSF says this does not go far enough.
In the second part of an exclusive interview with Generics Bulletin, BGMA chief executive Mark Samuels talks about the UK’s new biosimilars licensing pathway, future trade deals and IP, and efforts around repurposing generics, as well as looking ahead to how the UK’s vaccination program could reshape the COVID-19 pandemic.
Despite new requirements to include details of biologic exclusivity and intellectual property in the FDA’s Purple Book that come into effect on 25 June, experts believe information gaps for biosimilars developers may still exist.
Sun Pharma has become the latest ANDA sponsor to settle litigation with Celgene over Revlimid, shortly after Natco and partner Teva picked up the first ANDA approval for the blockbuster treatment for multiple myeloma.
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.